<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531410</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02871</org_study_id>
    <nct_id>NCT04531410</nct_id>
  </id_info>
  <brief_title>NETwork of Linoleic Acid Supplementation in Cystic Fibrosis</brief_title>
  <acronym>NETLACF</acronym>
  <official_title>Double-blind Randomized Controlled Study of Linoleic Acid Supplementation for 1 Year in Patients With Cystic Fibrosis - Influence on Clinical Status and Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Society of Pediatric Gastroenterology, Hepatology and Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Undernutrition is a common problem in patients with cystic fibrosis (CF) despite&#xD;
      international consensus that the patients shall be given 120-200% of energy recommendations.&#xD;
      Studies imply that one problem might be that the patients are not compensated for the&#xD;
      essential fatty acid deficiency (linoleic acid, LA), which is well known in these patients.&#xD;
      This deficiency is shown not to be due to fat malabsorption, but related to an increased&#xD;
      turnover of arachidonic acid, a transformation product of LA. This abnormality is related to&#xD;
      mutations associated with a more severe clinical phenotype. The most common and typical&#xD;
      symptom of LA deficiency is poor growth. Studies in animals have further indicated that many&#xD;
      of the symptoms in CF are related to the deficiency. A series of recent prospective studies&#xD;
      from Wisconsin corroborate the importance of LA for growth. In Sweden LA has been&#xD;
      supplemented to most patients since the late 70´, and the condition of patients have been&#xD;
      among the leading in the world regarding growth, pulmonary function and survival. Short-term&#xD;
      studies have shown better effect of LA supplementation compared to similar supply of energy&#xD;
      without including extra LA. There are few long-term studies, performed before the gene was&#xD;
      identified, giving very heterogeneous patient groups in regard to genotype, but with some&#xD;
      positive results on growth and physiology. It´s of interest that modern personalized&#xD;
      extremely expensive therapy with correctors and potentiators for Cystic Fibrosis&#xD;
      Transmembrane Conductance Regulator may influence lipid metabolism. LA might thus tentatively&#xD;
      be a cheap adjuvant to this modern therapy, but this has to be specially studied.&#xD;
&#xD;
      The aim of the study is to find if there are differences in clinical and metabolic outcome&#xD;
      between two groups, blindly given similar amount of extra calories, in one group consisting&#xD;
      of linoleic acid.The benefit for the patients would be great if the expected positive effect&#xD;
      can be proved in the planned study. The treatment will be cheap and without adverse effects.&#xD;
      From socioeconomic point of view is would be a great advantage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two group of matched children with CF were randomized to two type of oils given 20 g oil and&#xD;
      800 mg DHA daily for one year and anthropometry, pulmonary function, biochemistry, resting&#xD;
      energy expenditure, lipid mediators, inflammatory and intestinal markers were studied at&#xD;
      start and at 6 months and 1 year. Dietary intake was controlled and life quality recording at&#xD;
      start and end of study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel, double blind, randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The supplement only differ by colour on capsulae, no labelling</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Growth</measure>
    <time_frame>1 year</time_frame>
    <description>change in BMI, standard deviation score (SDS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>1 year</time_frame>
    <description>change in SDS body weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height</measure>
    <time_frame>1 year</time_frame>
    <description>change in SDS height</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>1 year</time_frame>
    <description>change in forced expiratory volume in one second (FEV1 % of predicted)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lipid mediators</measure>
    <time_frame>1 year</time_frame>
    <description>change in lipid mediators in blood and urine, ion trap- Mass Spectrometry, picoMol (&gt; 150 products of both the n-6 and n-3 series)</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical infectious status</measure>
    <time_frame>1 year</time_frame>
    <description>change in number exacerbations compare to previous year,</description>
  </other_outcome>
  <other_outcome>
    <measure>Influence on sodium status</measure>
    <time_frame>1 year</time_frame>
    <description>change in Sodium in sweat test, mol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>1 year</time_frame>
    <description>change in Cytokines, Proximity extension assays (PEA proteomics) picogram/ml</description>
  </other_outcome>
  <other_outcome>
    <measure>Metabolic marker</measure>
    <time_frame>1 year</time_frame>
    <description>Change in serum insulin growth factor -1 (IGF-1, nanogram/ml)</description>
  </other_outcome>
  <other_outcome>
    <measure>Energy metabolism</measure>
    <time_frame>1 year</time_frame>
    <description>Change in resting energy expenditure (REE/kg body weight)</description>
  </other_outcome>
  <other_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>1 year</time_frame>
    <description>Change in total bone mineral density by dual x-ray absorptiometry (DXA), gram/cm^2</description>
  </other_outcome>
  <other_outcome>
    <measure>Oral glucose tolerance</measure>
    <time_frame>1 year</time_frame>
    <description>Measure of glucose and insuline after oral glucose loading</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>Questionaire about health, physical activity, well being</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Linoleic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linoleic acid 13 g and 600 mg algal docosahexaenoic acid (DHA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oleic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oleic acid 13 g and 600 algal DHA</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>linoleic acid supplementation</intervention_name>
    <description>Oils given daily at morning meal with extra enzymes</description>
    <arm_group_label>Linoleic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>oleic acid supplementation</intervention_name>
    <description>Oils given at morning meal with extra enzymes</description>
    <arm_group_label>Oleic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Two mutations related to severe clinical status such as dF508, or other stop mutations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver cirrhosis and/or portal hypertension, transplantation or on transplantation&#xD;
             list, intake of lipid supplements the latest 2 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Try to have similar number of participants of the same sex and age for randomization</gender_description>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaroslaw Walkowiak, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Poznan, CF center, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carla Colombo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Milan, CF center, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olav Trond Storrösten, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo, CF center, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Regionale di Supporto per la Fibrosei Cistica, ASST Spedali civili, Univ of Brescia</name>
      <address>
        <city>Brescia</city>
        <state>Brescia - Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Milan</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwegian Resourse Center for Cystic Fibrosis, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poznan University of Medical Sciences</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Cystic fibrosis, Dept of Pediatrics, Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <state>Skåne</state>
        <zip>22242</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Strandvik B. Fatty acid metabolism in cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids. 2010 Sep;83(3):121-9. doi: 10.1016/j.plefa.2010.07.002. Epub 2010 Jul 31. Review.</citation>
    <PMID>20673710</PMID>
  </reference>
  <reference>
    <citation>Wheelock CE, Strandvik B. Abnormal n-6 fatty acid metabolism in cystic fibrosis contributes to pulmonary symptoms. Prostaglandins Leukot Essent Fatty Acids. 2020 Sep;160:102156. doi: 10.1016/j.plefa.2020.102156. Epub 2020 Jun 26. Review.</citation>
    <PMID>32750662</PMID>
  </reference>
  <reference>
    <citation>Strandvik B. Is the ENaC Dysregulation in CF an Effect of Protein-Lipid Interaction in the Membranes? Int J Mol Sci. 2021 Mar 8;22(5). pii: 2739. doi: 10.3390/ijms22052739. Review.</citation>
    <PMID>33800499</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Birgitta Strandvik, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>arachidonic acid,</keyword>
  <keyword>lipid mediators</keyword>
  <keyword>cytokines</keyword>
  <keyword>growth</keyword>
  <keyword>pulmonary function</keyword>
  <keyword>IGF-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The results will be anonymous and reported to peer review journals for publication. Beside the local PIs there will be other local staff involved and for the analyses also co-workers as shown in the study protocol which will be attached for review.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04531410/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Patients info consent</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04531410/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Parents info consent</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04531410/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

